Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer

Key Points

• Success of immune checkpoint inhibitors correlates with CD8 levels and TP53 status, suggesting a potential predictive role.
• The study reveals that specific biomarker analysis can guide treatment decisions for patients with EGFR mutations.
• Using biomarkers like CD8 and TP53 mutational status allows for a more tailored therapy approach in non-small cell lung cancer.
• This discovery highlights the need for personalized strategies in cancer care, particularly in targeting immune responses.

Abstract